Research programme: antibody therapeutics - Innovative Targeting Solutions/Merck

Drug Profile

Research programme: antibody therapeutics - Innovative Targeting Solutions/Merck

Alternative Names: HuTARG™ antibodies - Innovative Targeting Solutions/Merck

Latest Information Update: 16 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innovative Targeting Solutions; Merck & Co
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 07 Jun 2016 Early research in Undefined indication in USA and Canada (unspecified route)
  • 07 Jun 2016 Innovative Targeting Solutions and Merck agree to co-develop antibody therapeutics in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top